RE: “USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION”

As a methodological exercise, Kpozehuoen et al.'s Bayesian simulations are an important contribution in exploring the impact of different priors on reducing the size of a clinical acquired immunodeficiency syndrome trial. To compare the claimed efficiency gained by means of this Bayesian approa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of epidemiology 2005-11, Vol.162 (10), p.1033-1035
Hauptverfasser:	van Noord, Paulus A. H., van der Tweel, Ingeborg
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Infective Agents - therapeutic use Bayes Theorem Bayesian analysis Clinical trials Clinical Trials, Phase III as Topic - methods Endpoint Determination - methods Epidemiology HIV HIV Infections - drug therapy Human immunodeficiency virus Humans Randomized Controlled Trials as Topic - methods Research Design
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	As a methodological exercise, Kpozehuoen et al.'s Bayesian simulations are an important contribution in exploring the impact of different priors on reducing the size of a clinical acquired immunodeficiency syndrome trial. To compare the claimed efficiency gained by means of this Bayesian approach with an alternative method, van Nord et al. performed a sequential statistical analysis using the specifications given in the paper.
ISSN:	0002-9262 1476-6256
DOI:	10.1093/aje/kwi319